The term KIAA0226 Inhibitors refers to a class of chemical compounds specifically designed to interact with and modulate the activity of the KIAA0226 protein. KIAA0226, also known as AATF (apoptosis antagonizing transcription factor), is a multifunctional protein involved in various cellular processes, including transcriptional regulation, DNA repair, and maintenance of genomic stability. The development of inhibitors targeting KIAA0226 has emerged from the growing understanding of the protein's role in cellular homeostasis and its potential implications in various pathological conditions.
Structurally, KIAA0226 Inhibitors are designed with a focus on selectively binding to the active site or specific domains of the KIAA0226 protein, thereby interfering with its normal functions. These inhibitors often exploit the three-dimensional structure of the protein to achieve high affinity and selectivity, providing a molecular tool to study the biological consequences of inhibiting KIAA0226 activity. The design and optimization of KIAA0226 Inhibitors involve a combination of computational modeling, medicinal chemistry, and structural biology techniques to ensure the specificity and effectiveness of the inhibitors. Ongoing research in this area aims to further elucidate the molecular mechanisms underlying the interaction between these inhibitors and KIAA0226, shedding light on the intricate regulatory networks in which KIAA0226 participates and offering potential insights into novel strategies for modulating cellular processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING | 
|---|---|---|---|---|---|---|
| Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $56.00 $256.00 | 113 | |
| Inhibits autophagy by blocking class III PI3K, indirectly reducing Rubicon's regulatory effects. | ||||||
| Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $165.00 | ||
| Promotes degradation of class III PI3K complexes, potentially diminishing Rubicon's interaction. | ||||||
| SAR405 | 1523406-39-4 | sc-507416 | 1 mg | $125.00 | ||
| A selective PI3K inhibitor, which could alter Rubicon's function by inhibiting downstream signaling. | ||||||
| SBI-0206965 | 1884220-36-3 | sc-507431 | 10 mg | $122.00 | ||
| Inhibits the ULK1 kinase complex, potentially altering upstream autophagy signals affecting Rubicon. | ||||||
| Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
| A broad PI3K inhibitor that could nonspecifically reduce Rubicon's activity by altering autophagy flux. | ||||||
| LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
| Another broad PI3K inhibitor that may indirectly limit Rubicon's role by modulating autophagy. | ||||||
| Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
| Disrupts autophagosome fusion with lysosomes, potentially altering the process regulated by Rubicon. | ||||||
| hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $56.00 | 1 | |
| Similar to chloroquine, it can disrupt late stages of autophagy, indirectly affecting Rubicon. | ||||||
| Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
| Inhibits the vacuolar-type H+-ATPase, leading to disruption of autophagosome-lysosome fusion. | ||||||
| Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $65.00 $162.00 $650.00 $2550.00 | 109 | |
| A potent V-ATPase inhibitor similar to Bafilomycin A1, affecting autophagic regulation by Rubicon. | ||||||